Anticoagulation in the older adult: optimizing benefit and reducing risk.

Abstract:

:The risk for both arterial and venous thrombosis increases with age. Despite the increasing burden of strokes related to atrial fibrillation (AF) and venous thromboembolism (VTE) among older adults, the use of anticoagulant therapy is limited in this population due to the parallel increase in risk of serious hemorrhage. Understanding the risks and their underlying mechanisms would help to mitigate adverse events and improve persistence with these life-saving therapies. The objectives of this review are to: (1) elucidate the age-related physiologic changes that render this high risk subgroup susceptible to hemorrhage, (2) identify mutable risk factors and hazards contributing to an increased bleeding risk in older individuals, and (3) discuss interventions to optimize anticoagulation therapy in this population.

journal_name

Semin Thromb Hemost

authors

Ko D,Hylek EM

doi

10.1055/s-0034-1389083

subject

Has Abstract

pub_date

2014-09-01 00:00:00

pages

688-94

issue

6

eissn

0094-6176

issn

1098-9064

journal_volume

40

pub_type

杂志文章,评审
  • How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?

    abstract::Fibrin formed from fibrinogen is the main component of thrombi. Clot structure is characterized by fiber thickness and pore size, which differs within a given clot and between individuals. Plasma clot architecture is largely determined by the quantity and quality of fibrinogen. Plasma fibrinogen concentrations are mos...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1579636

    authors: Undas A

    更新日期:2016-06-01 00:00:00

  • New-Onset Atrial Fibrillation and Adverse In-Hospital Outcome in Patients with Acute Pulmonary Embolism.

    abstract::Atrial fibrillation (AF) can be secondary to acute pulmonary embolism (PE). This study aimed to investigate the prognostic impact of new-onset AF on patients with acute PE. In this study, 4,288 consecutive patients who were diagnosed with acute PE were retrospectively screened. In total, 77 patients with acute PE and ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0040-1718397

    authors: Tang RB,Jing YY,Xu ZY,Dong JZ,Du X,Wu JH,Yu RH,Long DY,Ning M,Sang CH,Jiang CX,Bai R,Liu N,Wen SN,Li SN,Chen X,Huang ST,Cui YK,Ma CS

    更新日期:2020-11-01 00:00:00

  • Low-molecular-weight heparin and cancer.

    abstract::Heparin is a familiar anticoagulant drug with properties that may impede tumor growth; it modifies properties of cells that contribute to malignant dissemination such as angiogenesis, growth factor and protease activity, immune function, proliferation, and gene expression. Heparin has antitumor effects in animal model...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-9499

    authors: Zacharski LR,Ornstein DL,Mamourian AC

    更新日期:2000-01-01 00:00:00

  • Genetic Background of von Willebrand Disease: History, Current State, and Future Perspectives.

    abstract::Sequencing of the gene encoding for von Willebrand factor (VWF) has brought new insight into the physiology of VWF as well as its pathophysiology in the context of von Willebrand disease (VWD). Molecular testing in VWD patients has shown high variability in the overall genetic background of this condition. Almost 600 ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-3402430

    authors: Zolkova J,Sokol J,Simurda T,Vadelova L,Snahnicanova Z,Loderer D,Dobrotova M,Ivankova J,Skornova I,Lasabova Z,Kubisz P,Stasko J

    更新日期:2020-06-01 00:00:00

  • Membrane cofactor protein and factor I: mutations and transplantation.

    abstract::Mutations in the genes for three complement regulators-complement factor H (CFH), membrane cofactor protein (MCP), and factor I (IF)-have now been described in patients with atypical HUS. The functional effects of these mutations have been studied in detail and have been shown to affect secretion, expression, and regu...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2006-939771

    authors: Kavanagh D,Goodship TH

    更新日期:2006-03-01 00:00:00

  • Factor XII in Hemostasis and Thrombosis: Active Player or (Innocent) Bystander?

    abstract::Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The lar...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1571338

    authors: Danese E,Montagnana M,Lippi G

    更新日期:2016-09-01 00:00:00

  • Protein C and the endothelium.

    abstract::With the continued accumulation of clinical and animal studies, it is becoming abundantly clear that the protein C anticoagulant pathway plays a critical role in the regulation of coagulation. Investigations also indicate that this pathway is intimately involved in the interaction of the coagulation and inflammatory s...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-1002779

    authors: Esmon NL,Esmon CT

    更新日期:1988-04-01 00:00:00

  • External quality assessment schemes in coagulation in Germany: between regulatory bodies and patient outcome.

    abstract::In the early 1980s, the first external quality assessment schemes (EQAS) regarding parameters of the coagulation laboratory were established in the daily routine of German laboratories. At present, the EQAS performed by INSTAND offers a wide range of global and single parameters of thrombosis and hemostasis. Only the ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-971812

    authors: Spannagl M,Dick A,Reinauer H

    更新日期:2007-04-01 00:00:00

  • Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality.

    abstract::Type 2B von Willebrand disease (VWD2B) is a rare, autosomal-dominant inherited bleeding disorder, characterized by an enhanced ristocetin-induced platelet aggregation in platelet-rich plasma and often with variable degree of thrombocytopenia and loss of high-molecular-weight multimers von Willebrand factor (VWF). All ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1579638

    authors: Castaman G,Federici AB

    更新日期:2016-07-01 00:00:00

  • Genetics of bleeding disorders in women.

    abstract::With the strides being made in the European, Canadian, and American prospective studies of von Willebrand disease (VWD) genotype and phenotype, genetics is increasingly playing a key role in the classification, understanding, and management of VWD. It is anticipated that as gene sequencing becomes easier and more comm...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0028-1103362

    authors: Novelli EM,Ragni MV

    更新日期:2008-09-01 00:00:00

  • Thrombin Generation and Cirrhosis: State of the Art and Perspectives.

    abstract::Epidemiological and laboratory studies performed in the last decades have changed our understanding of coagulopathy in cirrhosis, from a condition at increased risk of hemorrhagic events to one at higher thrombotic risk. However, it is not clear whether the decrease in factors that promote (except factor [F] VIII) ver...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0040-1715102

    authors: Lebreton A,Sinegre T,Lecompte T,Talon L,Abergel A,Lisman T

    更新日期:2020-09-01 00:00:00

  • Acute ischemic stroke.

    abstract::While case fatality rates in ischemic stroke tend to decline, the total number of strokes is expected to increase further in the future because of more people reaching a greater age. Acute ischemic stroke, usually caused by chronic arterial hypertension, in most cases is induced either by a sudden loss of perfusion pr...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-998991

    authors: Huber M,Heiss WD

    更新日期:1996-01-01 00:00:00

  • Intracerebral bleeding in patients on antithrombotic agents.

    abstract::Patients treated with oral anticoagulants (OAC) carry a 7- to 10-fold higher risk of intracerebral hemorrhage (ICH) than patients without OAC. ICH related to oral anticoagulation (OAC-ICH) is a particularly severe form of stroke. The overall incidence of OAC-ICH ranges between 2 and 9 per 100,000 population/year and i...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0033-1357506

    authors: Veltkamp R,Rizos T,Horstmann S

    更新日期:2013-11-01 00:00:00

  • Inhibitors in Hemophilia: Treatment Challenges and Novel Options.

    abstract::Hemophilia A (HA) and hemophilia B (HB) are rare congenital severe bleeding disorders, that may be controlled by proper administration of adequate prophylaxis with factor VIII (FVIII), and factor IX (FIX) concentrates, respectively, to prevent joint damage due to recurrent bleeding. However, approximately 30% of patie...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0037-1612626

    authors: Barg AA,Livnat T,Kenet G

    更新日期:2018-09-01 00:00:00

  • Standardization of the INR: how good is your laboratory's INR and can it be improved?

    abstract::The prothrombin time (PT) assay is the most clinically ordered coagulation test and is most often used for monitoring of vitamin K antagonist (VKA) therapy (e.g., warfarin), where results are expressed as an international normalized ratio (INR). The INR is in essence the patient's PT "mathematically adjusted" to a sta...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0028-1104538

    authors: Favaloro EJ,Adcock DM

    更新日期:2008-10-01 00:00:00

  • Protective action of polyelectrolytes on endothelium.

    abstract::These results show that heparin and dextran sulfate protect endothelial cells from oxygen-free radicals. Heparan sulfate and dermatan sulfate showed mild protection when measuring cell viability but none when examining the presence of LDH in media. These GAGs are obviously not as effective as heparin and dextran sulfa...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:

    authors: Hiebert L,Liu JM

    更新日期:1991-01-01 00:00:00

  • To mix or not to mix in lupus anticoagulant testing? That is the question.

    abstract::Mixing patient and normal plasma has been used for many years to assist with making decisions on which direction to proceed for further investigation of abnormally prolonged coagulation tests, namely, either individual coagulation factor measurement or the search for circulating anticoagulants. Mixing tests, however, ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0032-1304717

    authors: Tripodi A

    更新日期:2012-06-01 00:00:00

  • Targeting Nanotechnologies for the Treatment of Thrombosis and Cardiovascular Disease.

    abstract::Thrombosis is characterized by the formation of in vivo blood clots that are localized within arterial or venous blood vessels. These thrombi form beyond the need for physiologically healthy hemostatic responses and can lead to significant medical issues for affected individuals. Unfortunately, the existing standard-o...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-1697946

    authors: Palazzolo JS,Westein E,Hagemeyer CE,Wang TY

    更新日期:2020-07-01 00:00:00

  • Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies.

    abstract::Disseminated intravascular coagulation (DIC) is a syndrome characterized by systemic intravascular activation of coagulation leading to widespread deposition of fibrin in the circulation. There is ample experimental and pathological evidence that the fibrin deposition contributes to multiple organ failure. The massive...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2001-18862

    authors: Levi M,de Jonge E,van der Poll T,ten Cate H

    更新日期:2001-12-01 00:00:00

  • Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration.

    abstract::The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-996069

    authors: Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

    更新日期:1997-01-01 00:00:00

  • Pulmonary embolism in children.

    abstract::Pulmonary embolism (PE) has long been described in children. Nevertheless, most of the algorithms applied to patients within this age range, from diagnosis to therapy, have been adapted from adult protocols. This article reviews the progresses that occurred to PE in children placing them in historical perspective with...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0031-1297168

    authors: Brandão LR,Labarque V,Diab Y,Williams S,Manson DE

    更新日期:2011-10-01 00:00:00

  • Clinical utility of the PFA-100.

    abstract::The PFA-100 (platelet function analyzer) is a relatively new tool for the investigation of primary hemostasis. This article reviews the history of the PFA-100 and details its clinical utility in several settings. The PFA-100 was first introduced to us in 1995 in an issue of Seminars in Thrombosis And Hemostasis, which...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0029-1145254

    authors: Favaloro EJ

    更新日期:2008-11-01 00:00:00

  • Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.

    abstract::Polycystic ovarian syndrome (PCOS) affects 12 to 19% of women and has reproductive and metabolic features (endothelial dysfunction, increased diabetes, and cardiovascular risk factors). It also appears to have altered coagulation and fibrinolysis with a prothrombotic state with epidemiological evidence of increased ve...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 临床试验,杂志文章

    doi:10.1055/s-0035-1564837

    authors: Burchall GF,Piva TJ,Linden MD,Gibson-Helm ME,Ranasinha S,Teede HJ

    更新日期:2016-02-01 00:00:00

  • CD36 and macrophage scavenger receptor a modulate foam cell formation via inhibition of lipid-laden platelet phagocytosis.

    abstract::CD34 (+) progenitor cells are a promising source of regeneration in atherosclerosis or ischemic heart disease. However, as recently published, CD34(+) progenitor cells have the potential to differentiate not only into endothelial cells but also into foam cells upon interaction with platelets. The mechanism of platelet...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0030-1251499

    authors: Seizer P,Schiemann S,Merz T,Daub K,Bigalke B,Stellos K,Müller I,Stöckle C,Müller K,Gawaz M,May AE

    更新日期:2010-03-01 00:00:00

  • Anagrelide treatment in myeloproliferative disorders.

    abstract::Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2006-939437

    authors: Birgegard G

    更新日期:2006-04-01 00:00:00

  • Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency.

    abstract::Protein C replacement therapy with a monoclonal antibody purified, virus inactivated protein C concentrate was carried out in nine infants (three male, six female) with severe congenital protein C deficiency and life-threatening purpura fulminans and/or thrombosis associated with disseminated intravascular coagulation...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-1000658

    authors: Dreyfus M,Masterson M,David M,Rivard GE,Müller FM,Kreuz W,Beeg T,Minford A,Allgrove J,Cohen JD

    更新日期:1995-01-01 00:00:00

  • Bleeding Scores for the Diagnosis of von Willebrand Disease.

    abstract::Obtaining a personal history of bleeding is a critical component to the diagnosis of von Willebrand disease (VWD). The collection of this information can be challenging for physicians, however, as the reporting and interpretation of bleeding symptoms is subjective. The need for more precise quantification of bleeding ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1597289

    authors: Bowman ML,James PD

    更新日期:2017-07-01 00:00:00

  • Consequences of homocysteine export and oxidation in the vascular system.

    abstract::The risk for arteriosclerosis and thrombosis of patients with severe hyperhomocysteinemia is reduced by homocysteine-lowering therapy. Whether this is the case in patients with mild hyperhomocysteinemia remains to be proved. Another challenge for researchers is to establish a satisfying pathological mechanism of the v...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2000-8467

    authors: Blom HJ

    更新日期:2000-01-01 00:00:00

  • Stimulation of cell surface plasminogen activation by heparin and related polyionic substances.

    abstract::The functional operation of the cell surface pro-u-PA and plasminogen activating system has previously been shown to depend on the assembly of u-PA receptors, plasminogen binding sites, and their respective ligands at the focal adhesions of cell extensions. We now show that additional factors operate that affect the p...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1002610

    authors: Stephens RW,Pöllänen J,Tapiovaara H,Woodrow G,Vaheri A

    更新日期:1991-07-01 00:00:00

  • Developmental Hemostasis and Management of Central Venous Catheter Thrombosis in Neonates.

    abstract::Neonatal hemostasis differs qualitatively, but in particular quantitatively, from hemostasis in older children and adults. Nevertheless, hemostasis in healthy neonates is functionally stable with no tendency to bleeding or thrombotic complications. In sick neonates, however, risk factors may disrupt this equilibrium a...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0036-1592299

    authors: van Ommen CH,Sol JJ

    更新日期:2016-10-01 00:00:00